---
category: news
title: "Immunis.AI Reports Results of a Prospective Study of its RNAseq-Based Liquid-Biopsy in Early-Stage Prostate Cancer"
excerpt: "Immunis.AI, Inc., an immunogenomics platform company developing noninvasive blood-based tests to optimize patient care, today announced the publicatio"
publishedDateTime: 2021-10-12T02:13:00Z
originalUrl: "https://www.businesswire.com/news/home/20211011005698/en/Immunis.AI-Reports-Results-of-a-Prospective-Study-of-its-RNAseq-Based-Liquid-Biopsy-in-Early-Stage-Prostate-Cancer"
webUrl: "https://www.businesswire.com/news/home/20211011005698/en/Immunis.AI-Reports-Results-of-a-Prospective-Study-of-its-RNAseq-Based-Liquid-Biopsy-in-Early-Stage-Prostate-Cancer"
type: article
quality: 0
heat: 0
published: false

provider:
  name: Business Wire
  domain: businesswire.com

topics:
  - AI

secured: "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;wlck50BACCeKytKoeIz/1A=="
---

